D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $9 Price Target

Benzinga · 01/07 13:08
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $9 price target.